| Literature DB >> 27074593 |
Liujie Huo1, Wilfred A van der Donk1.
Abstract
Lantibiotics are a group of ribosomally synthesized and post-translationally modified peptides (RiPPs) exhibiting antimicrobial activity. They are characterized by the presence of the thioether-containing bisamino acids lanthionine and methyllanthionine. Here, we report a two-component lantibiotic from Bacillus cereus SJ1 with unusual structural features that we named bicereucin. Unlike all previous two-component lantibiotics, only one of the two peptides of bicereucin contains a lanthionine. The second peptide lacks any cysteines but contains several d-amino acids. These are installed by the dehydrogenase BsjJB, the activity of which was successfully reconstituted in vitro. The proteolytic removal of the leader peptide was also performed in vitro. Bicereucin displayed synergistic antimicrobial activities against Gram-positive strains including methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci as well as hemolytic activity. To illustrate the utility of the enzymes, an analog of the d-amino acid containing opioid dermorphin was successfully produced in E. coli by employing the dehydratase BsjM and the dehydrogenase NpnJA.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27074593 PMCID: PMC4851115 DOI: 10.1021/jacs.6b02513
Source DB: PubMed Journal: J Am Chem Soc ISSN: 0002-7863 Impact factor: 15.419
Figure 1(a) General biosynthetic route toward Lan and MeLan. (b) The biosynthetic gene cluster for bicereucin. (c) Post-translational maturation of bicereucin. Proteolytic cleavage sites are highlighted in yellow and purple.
Figure 2Structural analysis of Bsjα and Bsjβ. MS-MS fragmentation pattern of (a) AVE-Bsjα and (b) AVE-Bsjβ. (c) Stereochemistry of the introduced Ala using Marfey’s method: (I) Extracted ion chromatogram (EIC) of [M + H] = 342.1 ± 0.2 Da corresponding to FDAA-l- and d-Ala standards. (II) EIC of hydrolysate of AVE-Bsjα derivatized with FDAA. (III) EIC of hydrolysate of AVE-Bsjα derivatized with FDAA coinjected with d-Ala derivatized with FDAA. (d) Stereochemistry of Abu: (I) EIC of [M + H] = 356.1 ± 0.2 Da corresponding to FDAA-Abu standards. (II) EIC of hydrolysate of AVE-Bsjβ derivatized with FDAA. (III) EIC of hydrolysate of AVE-Bsjβ derivatized with FDAA coinjected with authentic d-Abu derivatized with FDAA. (e) ESI-Q-TOF MS of in vitro assay of BsjJB with BsjM-modified His6-BsjA1 followed by BsjT-150 digestion: (I) incubation with heat-denatured His-BsjJB as negative control. (II) Assay with His-BsjJB. (f) Structures of Bsjα and Bsjβ assigned in this work.
Figure 3Antimicrobial activity assays of bicereucin against Bacillus subtilis ATCC6633. (a) Agar diffusion growth assay: (I) blank, (II) Bsjα, (III) Bsjβ, (IV) Bsjα combined with Bsjβ; spotted total peptide amount: 1 nmol. (b) Isobologram demonstrating the optimal inhibitory ratio of Bsjα and Bsjβ.